Stately Bio raises $12M in seed funding, led by AIX Ventures. The funding will be used to scale its ML-powered live-cell imaging platform.
Stately Bio raises $12M in seed funding, led by AIX Ventures. The funding will be used to scale its ML-powered live-cell imaging platform.
05/01/25, 4:10 PM
Location
palo altoMoney raised
$12 million
Industry
therapeutics
biotechnology
Round Type
seed
Investors
Tom Berry, Jeremy Wertheimer, Jeff Dean, Axial Vc, Box One Ventures, Mitsui Global Investment, Caffeinated Capital, Village Global, Foothill Ventures, Dimension Capital, Aix Ventures
Stately Bio, a Palo Alto based startup, has raised $12M in seed funding. The round was led by AIX Ventures with multiple investors including Dimension Capital and Foothill Ventures. The company plans to use the funding to enhance its technology and develop stem cell-derived therapeutics. Founded in 2022, Stately Bio is focusing on using machine learning in regenerative medicine.
Company Info
Location
palo alto, california, united states
Additional Info
Stately Bio is a biotechnology company building machine learning for regenerative medicine. The company has developed a computational platform that enables rapid, real-time insights into cell identity, quality, and behavior based on live-cell imaging. Founded in 2022, Stately Bio focuses on developing cell therapies using an ML-powered live-cell imaging platform.